n******7
发帖数: 12463 | 1 这是今天的一个新闻，Steve Horvath的研究我比较熟悉，之前还做过类似的领域。
这才叫原创的，临床相关的研究。不是随便扯个DL的名号就是。
顺便说个花边新闻，Steve之前读到一篇烂文，忘记是不是那个俄罗斯公司的了，也是
关于aging这块的生物信息分析。他想这块我专业啊，这种烂文是misleading，我得去
评论一下。于是就发了个comment，说这里面这里有问题，那里有问题。结果没多久，
居然收到一封那个公司寄来的律师信，威胁他必须撤销这个comment，哈哈哈
－－－
Life Insurer GWG Acquires Rights to Epigenetic Mortality Predictor Tech
May 05, 2017 | staff reporter
NEW YORK (GenomeWeb) – GWG Holdings, the parent company of life insurance
firm GWG Life, announced today that it has exclusively licensed technology
from the University of California, Los Angeles, related to the use of
epigenetic markers to predict life expectancy.
The technology is based on the work of UCLA's Steve Horvath, who has shown
that DNA methylation age, measured in blood, could predict all-cause
mortality later in life, independent of health status, lifestyle, and known
genetic factors.
In November, GWG optioned the technology — which measures the methylation
of certain CpG sites as markers of biological aging — so GWG Life could
develop it as a method for generating more accurate life expectancy
projections. Earlier this year, GWG Life began collecting and analyzing
epigenetic data from policyholders selling their life insurance.
GWG has now exercised its option, picking up the exclusive rights to the
technology for use in life insurance and related industries. Additional
terms of the deal were not disclosed.
"Even though we've only scratched the surface, epigenetics are already
showing much more promise for assessing human health than merely looking at
the genetic sequence," Brian Chen, vice president of research and analytics
at GWG Life and Horvath collaborator, said in a statement. |
|
